|
JPS501B1
(enExample)
|
1970-05-19 |
1975-01-06 |
|
|
|
EP3156062A1
(en)
|
2010-05-17 |
2017-04-19 |
Sangamo BioSciences, Inc. |
Novel dna-binding proteins and uses thereof
|
|
US9637739B2
(en)
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
|
WO2013141680A1
(en)
|
2012-03-20 |
2013-09-26 |
Vilnius University |
RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
|
|
WO2013151663A1
(en)
*
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
LT3401400T
(lt)
|
2012-05-25 |
2019-06-10 |
The Regents Of The University Of California |
Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui
|
|
PL4397760T3
(pl)
|
2012-10-23 |
2026-03-30 |
Toolgen Incorporated |
Kompozycja do rozszczepiania docelowego dna zawierająca prowadzące rna specyficzne dla docelowego dna i kwas nukleinowy kodujący białko cas lub białko cas oraz jej zastosowanie
|
|
EP3135765A1
(en)
|
2012-12-06 |
2017-03-01 |
Sigma-Aldrich Co. LLC |
Crispr-based genome modification and regulation
|
|
EP2896697B1
(en)
|
2012-12-12 |
2015-09-02 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions for sequence manipulation
|
|
IL239317B
(en)
|
2012-12-12 |
2022-07-01 |
Broad Inst Inc |
Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
SG10201912991WA
(en)
|
2012-12-17 |
2020-03-30 |
Harvard College |
Rna-guided human genome engineering
|
|
US20140235933A1
(en)
|
2013-02-20 |
2014-08-21 |
Regeneron Pharmaceuticals, Inc. |
Genetic modification of rats
|
|
JP2016507244A
(ja)
|
2013-02-27 |
2016-03-10 |
ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ ＭｕｅｎｃｈｅｎＤｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） |
Ｃａｓ９ヌクレアーゼによる卵母細胞における遺伝子編集
|
|
US9234213B2
(en)
*
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
|
US10378027B2
(en)
|
2013-03-15 |
2019-08-13 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
|
JP2016522679A
(ja)
|
2013-04-04 |
2016-08-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
|
|
US20140356956A1
(en)
|
2013-06-04 |
2014-12-04 |
President And Fellows Of Harvard College |
RNA-Guided Transcriptional Regulation
|
|
WO2015048577A2
(en)
|
2013-09-27 |
2015-04-02 |
Editas Medicine, Inc. |
Crispr-related methods and compositions
|
|
WO2015089486A2
(en)
*
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
|
EP3674408A1
(en)
|
2014-06-16 |
2020-07-01 |
The Johns Hopkins University |
Compositions and methods for the expression of crispr guide rnas
|
|
US20150376587A1
(en)
|
2014-06-25 |
2015-12-31 |
Caribou Biosciences, Inc. |
RNA Modification to Engineer Cas9 Activity
|
|
EP3169309B1
(en)
|
2014-07-16 |
2023-05-10 |
Novartis AG |
Method of encapsulating a nucleic acid in a lipid nanoparticle host
|
|
WO2016049258A2
(en)
*
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
WO2016106236A1
(en)
*
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
EP3237624B1
(en)
|
2014-12-23 |
2020-01-29 |
Syngenta Participations AG |
Methods and compositions for identifying and enriching for cells comprising site specific genomic modifications
|
|
JP6817215B2
(ja)
|
2015-03-03 |
2021-01-20 |
ザ ジェネラル ホスピタル コーポレイション |
変更ＰＡＭ特異性を有する遺伝子操作ＣＲＩＳＰＲ−Ｃａｓ９ヌクレアーゼ
|
|
WO2016149484A2
(en)
|
2015-03-17 |
2016-09-22 |
Temple University Of The Commonwealth System Of Higher Education |
Compositions and methods for specific reactivation of hiv latent reservoir
|
|
WO2016197133A1
(en)
*
|
2015-06-04 |
2016-12-08 |
Protiva Biotherapeutics, Inc. |
Delivering crispr therapeutics with lipid nanoparticles
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
WO2017004279A2
(en)
|
2015-06-29 |
2017-01-05 |
Massachusetts Institute Of Technology |
Compositions comprising nucleic acids and methods of using the same
|
|
US12110490B2
(en)
*
|
2015-12-18 |
2024-10-08 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
|
US11845933B2
(en)
|
2016-02-03 |
2023-12-19 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide RNA and its applications
|
|
SI3436077T1
(sl)
|
2016-03-30 |
2025-07-31 |
Intellia Therapeutics, Inc. |
Formulacije lipidnih nanodelcev za komponente crispr/cas
|
|
AU2017253107B2
(en)
*
|
2016-04-19 |
2023-07-20 |
Massachusetts Institute Of Technology |
CPF1 complexes with reduced indel activity
|
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
|
MY206324A
(en)
|
2016-12-08 |
2024-12-10 |
Intellia Therapeutics Inc |
Modified guide rnas
|
|
AU2017376950B2
(en)
*
|
2016-12-16 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions
|
|
EP3687581A1
(en)
|
2017-09-29 |
2020-08-05 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
|
JP7139419B2
(ja)
*
|
2017-09-29 |
2022-09-20 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒト化ｔｔｒ遺伝子座を含む非ヒト動物および使用方法
|